TB data overview
- Population: Fetching... (Fetching...)
- Current health expenditure (% of GDP): Fetching... (Fetching...)
- WHO region: Fetching...
- World Bank income level: Fetching...
A. TB EPIDEMIOLOGICAL PROFILE
A.1. Population
A.1.1 Total population number
A.1.2 Population number by age group and sex, 2023
Estimates of TB burden
A.2. Incidence
A.2.1 Estimated number of incident TB cases
A.2.2 Estimated TB incidence rate per 100 000 population
A.2.3 Estimated number of incident TB cases by age group and sex, 2023
A.2.4 Estimated number of incident TB cases by age and sex per 100 000 population, 2023
A.2.5 Percentage change in TB incidence rate between 2015 and 2023
A.2.6 Number of people with TB attributable to five risk factors, 2023
A.2.7 Estimated number of incident cases of rifampicin-resistant TB
A.2.8 Estimated rifampicin-resistant TB incidence rate per 100 000 population
A.2.9 Estimated percentage of TB cases with rifampicin resistance
A.3. Mortality
A.3.1 Estimated number of TB deaths
A.3.2 Estimated TB mortality rate per 100 000 population
A.3.3 Estimated number of TB deaths by age and sex, 2023
A.3.4 TB estimated mortality rate by age and sex per 100 000 population, 2023
A.3.5 Percentage change in number of TB deaths (HIV-negative and HIV-positive) between 2015 and 2023
A.4. TB screening and prevention
A.4.1 Percentage of household contacts (or all close contacts) evaluated for TB
A.4.2 Number of individuals started on shorter TB preventive treatment regimens containing rifampicin or rifapentine
A.4.3 Number of household contacts (or close TB contacts) started on TB preventive treatment
A.4.4 Percentage of household contacts (or all close contacts) under 5 years who were started on TB preventive treatment out of those eligible
A.4.5 Percentage of household contacts (or all close contacts) of all ages who were started on TB preventive treatment out of those eligible
A.4.6 Percentage of household contacts (or all close contacts) who completed TB preventive treatment
A.4.7 Number of people living with HIV started on TB preventive treatment
A.4.8 Percentage of people living with HIV newly initiated on ART who were started on TB preventive treatment out of those eligible
A.4.9 Percentage of people living with HIV who completed TB preventive treatment
TB notification
A.5. Detection
A.5.1 Number of people diagnosed with a new episode of TB
A.5.2 People diagnosed with a new episode of TB per 100 000 population
A.5.3 Number of people diagnosed with a new episode of TB by age groups and sex, 2023
A.5.4 People diagnosed with a new episode of TB by age and sex per 100 000 population, 2023
A.5.5 Number of people diagnosed with TB by bacteriological confirmation and site of disease
A.5.6 TB treatment coverage (%)
A.6. HIV testing and antiretroviral therapy services
A.6.1 TB/HIV cascade of care - Number notified and HIV tested
A.6.2 TB/HIV cascade of care - Number HIV-positive and ART enrolment
A.6.3 TB/HIV cascade of care, 2023
A.7. Drug-resistant TB
A.7.1 Rifampicin-resistant TB cascade of care
Number pulmonary lab confirmed and tested for RR-TBA.7.2 Rifampicin-resistant TB cascade of care
Number diagnosed with RR-TB and enrolled into treatmentA.7.3 Rifampicin-resistant TB cascade of care, 2023
Metadata
Glossary and definitions
| Estimated number of incident TB cases | Estimated number of new and recurrent tuberculosis (TB) cases arising in a given year. All forms of TB are included, including cases in people living with HIV and those with drug-resistant TB. Uncertainty bounds are provided in addition to best estimates. |
|---|---|
| Estimated number of incident TB cases per 100 000 population | Estimated number of new and recurrent TB cases arising in a given year expressed as a rate per 100 000 population. All forms of TB are included, including cases in people living with HIV and those with drug-resistant TB. Uncertainty bounds are provided in addition to best estimates. |
| Percentage change in estimated incidence rate per 100 000 population between 2015 and 2023 | The percentage change in estimated incidence rate per 100 000 population is a core End TB Strategy indicator used to monitor progress toward achieving the End TB Strategy goal of ending the global TB epidemic by 2035, with a targeted 90% reduction in TB incidence rate compared to 2015. Milestones to be reached before 2035 include a 50% reduction by 2025 and an 80% reduction by 2030. |
| Estimated number of TB deaths | Estimated number of deaths attributable to TB in a given year. When people with AIDS die from TB, HIV is registered as the underlying cause of death, while TB is recorded as a contributory cause. Data is disaggregated into TB deaths excluding HIV, TB/HIV deaths and total TB deaths. |
| Estimated number of TB mortality rate per 100 000 population | Estimated number of deaths attributable to TB in a given year per 100 000 population. When people with AIDS die from TB, HIV is registered as the underlying cause of death and TB is recorded as contributory cause. Data is disaggregated into TB deaths excluding HIV, TB/HIV deaths and total TB deaths. |
| Percentage change in number of TB deaths (HIV-negative and HIV positive) between 2015 and 2023 | The percentage change in estimated number of TB deaths is a core End TB Strategy indicator used to monitor progress toward achieving the End TB Strategy goal of ending the global TB epidemic by 2035, with a targeted 95% reduction in number of TB deaths compared to 2015. Milestones to be reached before 2035 include a 75% reduction by 2025 and an 90% reduction by 2030. |
| Number of people diagnosed with a new episode of TB | The number of new and recurrent cases of TB detected in a given year, including those with an unknown previous TB treatment history. All forms of TB are included, including cases in people living with HIV and those with drug-resistant TB. Case detection refers to the diagnosis of TB in a person, which is then reported within the national surveillance system (also known as notification) and subsequently to WHO. |
| People diagnosed with a new episode of TB per 100 000 | The number of new and recurrent cases for TB detected in a given year, including those with unknown previous TB treatment history per 100 000 population. All forms of TB are included, including cases in people living with HIV and those with drug-resistant TB. |
| Number of people diagnosed with TB by bacteriological confirmation and site of disease | The number of people diagnosed with TB in a given year. This includes people diagnosed with a new episode of TB and those re-registered for TB treatment. All forms of TB are included, including cases in people living with HIV and cases with drug-resistant TB. A detailed breakdown of this indicator is as follows: New episode: A person with TB disease who is classified as a new case, a recurrent case or a case with unknown previous treatment history (i.e. any case apart from a re-registered case). Bacteriologically confirmed pulmonary TB: the number of people with a new episode of TB in a given year who have pulmonary localization of disease and test positive using any WHO-recommended rapid diagnostics, such as Xpert MTB/RIF, Ultra, Truenat MTB, MTB Plus, TB-LAMP or LF-LAM, as well as culture-positive or smear-positive cases. Clinically diagnosed pulmonary TB: the number of people with a new episode of TB in a given year who have pulmonary localization of disease and do not fulfil the criteria for bacteriological confirmation. Extrapulmonary tuberculosis: number of people diagnosed with a new episode of TB in a given year who have extrapulmonary localization. |
Tuberculosis treatment coverage | The number of people diagnosed with a new episode of TB in a given year, divided by the estimated number of incident TB cases in the same year, expressed as a percentage. |
| TB/HIV cascade of care | The TB/HIV cascade of care provides an approach for assessing the continuum of care for individuals co-infected with TB and HIV, from HIV testing and diagnosis to the initiation of antiretroviral therapy (ART). TB/HIV cascade of care includes the following: Notified: the number of people diagnosed with a new episode of TB. All forms of TB are included, including cases in people living with HIV and those with drug-resistant TB. HIV tested: the number of people diagnosed with a new episode of TB who were tested for HIV at the time of TB diagnosis or with known HIV status at the time of TB diagnosis. HIV-positive: the number of people diagnosed with a new episode of TB that are HIV-positive. HIV on ART: the number of people diagnosed with a new episode of TB who are HIV-positive and that have started or continued on ART. |
| Rifampicin-resistant TB cascade of care | The rifampicin-resistant TB cascade of care provides an approach for assessing the continuum of care for individuals with rifampicin-resistant TB starting from people with pulmonary laboratory confirmed TB to rifampicin susceptibility testing, diagnosis and enrollment into second-line TB treatment. The rifampicin-resistant TB cascade of care includes the following: Pulmonary laboratory-confirmed TB: the number of people diagnosed with a pulmonary TB (new episode and re-registered) whose disease was bacteriologically confirmed. Testing for drug susceptibility: the number of people diagnosed with bacteriologically confirmed pulmonary TB who were tested for susceptibility to rifampicin. Diagnosed with rifampicin-resistant TB: the number of people diagnosed with bacteriologically confirmed pulmonary TB that is resistant to rifampicin. Enrolled into treatment: The number of people diagnosed with rifampicin-resistant TB and registered as a TB case who started second line TB treatment. |
Copyright and licensing
| Copyright | Attribution 4.0 International (CC BY 4.0) |
|---|---|
| License | The World Health Organization (“WHO”) encourages public access and use of the data that it collects and publishes on its web site data.who.int. The data are organized in datasets and made available in machine-readable format (“Datasets”). The Datasets have been compiled from data provided by WHO’s Member States under the WHO policy on the use and sharing of data collected by WHO in Member States outside the context of public health emergencies. Use of the data derived from the Datasets, which may appear in formats such as tables and charts, is also subject to these Terms and Conditions. Datasets may include data describing the Dataset called “Metadata”. If any datasets are credited to a source other than WHO, then those materials are not covered by these Terms and Conditions, and permission should be sought from the source provided. You are responsible for determining if this is the case, and if so, you are responsible for obtaining any necessary permission from the sources indicated. The risk of claims resulting from infringement of any third-party-owned component in the materials rests solely with you. You may use our application programming interfaces (“APIs”) to facilitate access to the Datasets, whether through a separate web site or through another type of software application. By using the Datasets or any presentations of data derived from them, or by using our APIs in connection with the Datasets, you agree to be bound by these Terms and Conditions, as may be amended from time to time by WHO at its sole discretion. Unless specifically indicated otherwise, these Datasets are provided to you under a Creative Commons Attribution 4.0 International License (CC BY 4.0), with the additional terms below. The basic terms applicable to the CC BY 4.0 license may be accessed here. By downloading or using the Datasets, you agree to comply with the terms of the CC BY 4.0 license, as well as the following mandatory and binding addition: Any dispute relating to the interpretation or application of this license shall, unless amicably settled, be subject to conciliation. In the event of failure of the latter, the dispute shall be settled by arbitration. The arbitration shall be conducted in accordance with the modalities to be agreed upon by the parties or, in the absence of agreement, with the UNCITRAL Arbitration Rules. The parties shall accept the arbitral award as final. |
| Permission type | Publicly accessible |
| Prohibited uses | You shall not attempt to de-anonymise the Datasets or use the Datasets in a manner that falsifies or misrepresents their content. You shall not, in connection with your use of the Datasets published on data.who.int, state or imply that WHO endorses, or is affiliated with, you, or that WHO endorses your use of data.who.int, or any content, output, or analysis resulting from or related to the data.who.int, or any entity, organization, company, product or services. |
| Citation | World Health Organization 2025 data.who.int, WHO TB dashboard [Dashboard]. https://data.who.int/dashboards/tuberculosis/ |
| Disclaimer | WHO reserves the right at any time and from time to time to modify or discontinue, temporarily or permanently, the Datasets, or any means of accessing or utilizing the Datasets with or without prior notice to you. Maps All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas). The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the accuracy of the Datasets. However, the Datasets are being provided without warranty of any kind, either expressed or implied. You will be solely responsible for your use of the Datasets. In no event shall WHO be liable for any damages arising from such use. For full disclaimers, terms of use and your indemnification of WHO, please visit Terms and Conditions. |